Seneca Biopharma, Inc.
If you purchased Seneca Biopharma, Inc. securities and would like to join the action, please click "Join This Action" below.
SENECA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF SENECA BIOPHARMA, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – SNCA
December 17, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Seneca Biopharma, Inc. (NASDAQ: SNCA) and Leading BioSciences, Inc. is fair to Seneca shareholders.
The investigation concerns whether Seneca and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Seneca shareholders; and (2) disclose all material information necessary for Seneca shareholders to adequately assess and value the merger. On behalf of Seneca shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.